1. Home
  2. TCBI vs ACLX Comparison

TCBI vs ACLX Comparison

Compare TCBI & ACLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

TCBI

Texas Capital Bancshares Inc.

HOLD

Current Price

$93.50

Market Cap

3.9B

Sector

Finance

ML Signal

HOLD

Logo Arcellx Inc.

ACLX

Arcellx Inc.

HOLD

Current Price

$69.53

Market Cap

4.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TCBI
ACLX
Founded
1996
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.9B
4.2B
IPO Year
N/A
2022

Fundamental Metrics

Financial Performance
Metric
TCBI
ACLX
Price
$93.50
$69.53
Analyst Decision
Hold
Strong Buy
Analyst Count
10
9
Target Price
$87.50
$115.50
AVG Volume (30 Days)
433.2K
1.2M
Earning Date
01-22-2026
11-05-2025
Dividend Yield
N/A
N/A
EPS Growth
2948.16
N/A
EPS
6.10
N/A
Revenue
$1,149,977,000.00
$35,898,000.00
Revenue This Year
$47.92
N/A
Revenue Next Year
$7.89
$302.49
P/E Ratio
$15.33
N/A
Revenue Growth
39.14
N/A
52 Week Low
$59.37
$47.86
52 Week High
$94.61
$94.07

Technical Indicators

Market Signals
Indicator
TCBI
ACLX
Relative Strength Index (RSI) 67.08 33.01
Support Level $90.59 $66.00
Resistance Level $94.32 $75.03
Average True Range (ATR) 2.31 5.23
MACD 0.67 -1.69
Stochastic Oscillator 93.30 12.96

Price Performance

Historical Comparison
TCBI
ACLX

About TCBI Texas Capital Bancshares Inc.

Texas Capital Bancshares Inc is a registered bank holding company and a full-service financial services firm that delivers customised solutions to businesses, entrepreneurs and individual customers. It is a secured lender with the majority of the loans held for investment, excluding mortgage finance loans and other national lines of business. Texas Capital has established commercial banking, consumer banking, investment banking and wealth management capabilities.

About ACLX Arcellx Inc.

Arcellx Inc a clinical-stage biotechnology company reimagining cell therapy through the development of immunotherapies for patients with cancer and other incurable diseases. Its pipeline includes Multiple Myeloma, Acute Myeloid Leukemia, Non-Oncology, and Solid Tumors.

Share on Social Networks: